#1 Clinical Trials Search in Europe

Fluorodopa (18F)

Fluorodopa (18F), a radioactive tracer used in positron emission tomography (PET) scans, is being studied in several clinical trials to improve the diagnosis and understanding of various neurological conditions. These trials aim to evaluate its effectiveness in detecting brain tumors, assessing Parkinson’s disease, and investigating brain metastases and apathy in stroke patients. The research could potentially lead to better diagnostic tools and treatment strategies for these challenging neurological disorders.

Table of Contents

What is FLUORODOPA (18F)?

FLUORODOPA (18F), also known as F-DOPA, is a radioactive diagnostic agent used in medical imaging[1]. It’s a solution for injection that contains a small amount of radioactive material. This substance is used in a special type of imaging called Positron Emission Tomography (PET) to help doctors see detailed pictures of the brain[2].

How it Works

When injected into the body, FLUORODOPA (18F) mimics a natural substance called dopamine. Dopamine is a chemical messenger in the brain that’s important for movement, mood, and other functions. The radioactive element in FLUORODOPA (18F) allows special cameras to track where it goes in the brain, creating detailed images that can help doctors diagnose various conditions[3].

Medical Conditions Diagnosed

FLUORODOPA (18F) is used to diagnose several brain-related conditions:

  • Low-Grade Gliomas: These are slow-growing brain tumors. FLUORODOPA (18F) can help detect these tumors, especially when they don’t show up clearly on regular MRI scans[1].
  • Parkinson’s Disease: This is a condition that affects movement. FLUORODOPA (18F) can help doctors see how dopamine is working in the brains of people with Parkinson’s[2].
  • Brain Metastases: These are cancer cells that have spread to the brain from other parts of the body. FLUORODOPA (18F) can help detect these metastases in patients with lung cancer, breast cancer, or melanoma[3].
  • Apathy after Stroke: This is a condition where stroke patients lose motivation or interest. FLUORODOPA (18F) is being studied to understand how changes in brain chemistry might contribute to this condition[4].

How it’s Administered

FLUORODOPA (18F) is given as an injection into a vein (intravenously). The dose is usually calculated based on the patient’s weight, typically around 2 MBq per kilogram of body weight[1]. After the injection, the patient will need to wait for a short period before the PET scan is performed. This allows the substance to circulate through the body and reach the brain.

Safety Considerations

While FLUORODOPA (18F) is generally considered safe, there are some important points to consider:

  • It should not be used in pregnant or breastfeeding women[3].
  • Patients should inform their doctor if they have any allergies or medical conditions.
  • The radiation exposure from this test is relatively low and considered safe for diagnostic purposes.
  • Some medications may interfere with the test, so patients should inform their doctor about all medications they’re taking[4].

Ongoing Research

Scientists are continually studying new ways to use FLUORODOPA (18F) to improve diagnosis and treatment of brain conditions. Current research includes:

  • Using FLUORODOPA (18F) to predict which brain tumors might grow more aggressively[1].
  • Studying how FLUORODOPA (18F) might help in the diagnosis and treatment of Parkinson’s disease[2].
  • Investigating whether FLUORODOPA (18F) can improve the detection of brain metastases in cancer patients[3].
  • Exploring how FLUORODOPA (18F) might help understand brain chemistry changes in stroke patients with apathy[4].

These ongoing studies aim to expand our understanding of brain disorders and potentially lead to better treatments in the future.

Aspect Details
Primary Uses Diagnostic imaging for brain tumors, Parkinson’s disease, brain metastases, and apathy in stroke patients
Imaging Technique Positron Emission Tomography (PET) scans
Key Advantages Visualization of dopamine activity, detection of non-contrast enhancing tumors, assessment of brain metastases
Study Types Phase II and III clinical trials
Patient Populations Adults with suspected low-grade gliomas, Parkinson’s disease patients, cancer patients with brain metastases, stroke patients
Administration Intravenous injection
Safety Considerations Low radiation exposure, contraindications for certain medications and conditions
Potential Impact Improved diagnosis and characterization of brain tumors, better understanding of Parkinson’s disease and apathy mechanisms

FAQ

  • What is Fluorodopa (18F) and how is it used in medical imaging? Fluorodopa (18F) is a radioactive tracer used in positron emission tomography (PET) scans. It helps visualize brain activity and is particularly useful for imaging dopamine-related processes in the brain. This makes it valuable for studying conditions like Parkinson's disease and certain brain tumors.
  • What types of neurological conditions are being studied using Fluorodopa (18F)? Clinical trials are using Fluorodopa (18F) to study various neurological conditions, including low-grade gliomas (a type of brain tumor), Parkinson's disease, brain metastases from lung, breast, and melanoma cancers, and apathy in stroke patients.
  • How might Fluorodopa (18F) improve the diagnosis of brain tumors? Fluorodopa (18F) PET scans may help characterize brain tumors that don't show contrast enhancement on MRI. This could potentially lead to earlier and more accurate diagnosis of aggressive tumors, especially in cases of suspected low-grade gliomas.
  • Is Fluorodopa (18F) being used to study Parkinson's disease? Yes, Fluorodopa (18F) is being used in clinical trials to evaluate its effectiveness in assessing Parkinson's disease. It can help visualize dopamine activity in the brain, which is crucial for understanding and potentially treating this condition.
  • Are there any risks associated with using Fluorodopa (18F) in these clinical trials? While Fluorodopa (18F) is generally considered safe for diagnostic use, it does involve exposure to a small amount of radiation. The clinical trials carefully monitor patients for any potential side effects or risks. Patients with certain conditions or taking specific medications may be excluded from participating in these trials to ensure safety.

Ongoing Clinical Trials on Fluorodopa (18F)

  • Study on Apathy in Stroke Patients Using Fluoroethoxybenzovesamicol F-18 and Fluorodopa (18F)

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Fluorodopa (18F) for Diagnosing Low-Grade Glioma in Patients Without MRI Contrast Enhancement

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Long-term safety and effectiveness follow-up study of AB-1005 gene therapy in patients with Parkinson’s disease or multiple system atrophy

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Detecting Untreated Brain Metastases in Lung, Breast, and Melanoma Cancer Patients Using Fluorodopa (18F)

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Fluorodopa (18F): A radioactive tracer used in positron emission tomography (PET) scans to visualize brain activity, particularly useful for imaging dopamine-related processes in the brain.
  • Positron Emission Tomography (PET): A medical imaging technique that uses radioactive tracers to visualize and measure metabolic processes in the body.
  • Glioma: A type of tumor that occurs in the brain and spinal cord, arising from glial cells that support and protect nerve cells.
  • Metastases: Cancer cells that have spread from the primary site to other parts of the body, forming new tumors.
  • Apathy: A lack of interest, enthusiasm, or concern; in medical contexts, it can be a symptom of various neurological or psychiatric conditions.
  • Dopamine: A neurotransmitter in the brain that plays a crucial role in movement, motivation, and reward.
  • MRI: Magnetic Resonance Imaging, a medical imaging technique that uses strong magnetic fields and radio waves to produce detailed images of the body's internal structures.
  • Parkinson's Disease: A progressive nervous system disorder that affects movement, often causing tremors, stiffness, and difficulty with balance and coordination.
  • Cholinergic System: A part of the nervous system that uses the neurotransmitter acetylcholine, important for memory, attention, and muscle control.
  • Stroke: A medical condition where poor blood flow to the brain results in cell death, potentially causing lasting brain damage, long-term disability, or death.

References

  1. http://clinicaltrials.eu/trial/study-on-fluorodopa-18f-for-diagnosing-low-grade-glioma-in-patients-without-mri-contrast-enhancement/
  2. http://clinicaltrials.eu/trial/study-of-aav2-gdnf-for-adults-with-moderate-parkinsons-disease-using-a-drug-combination/
  3. http://clinicaltrials.eu/trial/study-on-detecting-untreated-brain-metastases-in-lung-breast-and-melanoma-cancer-patients-using-fluorodopa-18f/
  4. http://clinicaltrials.eu/trial/study-on-apathy-in-stroke-patients-using-fluoroethoxybenzovesamicol-f-18-and-fluorodopa-18f/